| 2026-12-01in 98 d | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) | BIIBBiogen | Phase 3 | Antibody-mediated Rejection | Active, not recruiting |
| 2026-12-01in 98 d | A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 | BMYBristol-Myers Squibb | Phase 4 | Systemic Lupus Erythematosus | Recruiting |
| 2026-12-01in 98 d | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | CMPXCompass Therapeutics | Phase 2/3 | Biliary Tract Cancer | Active, not recruiting |
| 2026-12-01in 98 d | An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers. | RANIRANI Therapeutics | Phase 1 | Obesity | Recruiting |
| 2026-12-01in 98 d | Study of Min-Max APAP Recommender Tool | RMDResMed | Not applicable | Obstructive Sleep Apnea | Not yet recruiting |
| 2026-12-01in 98 d | INFORMing Patients With Oximetry Data to Improve MAD Engagement | RMDResMed | Phase 4 | Obstructive Sleep Apnea | Not yet recruiting |
| 2026-12-01in 98 d | Descartes-08 for Patients With Systemic Lupus Erythematosus | RNACCartesian Therapeutics | Phase 2 | Systemic Lupus Erythematosus | Active, not recruiting |
| 2026-12-01in 98 d | A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD | SNYSanofi | Phase 3 | COPD | Active, not recruiting |
| 2026-12-01in 98 d | Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older | SNYSanofi | Phase 1/2 | Pandemic Influenza Immunization, Healthy Volunteers | Active, not recruiting |
| 2026-12-01in 98 d | A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | VNDAVanda Pharmaceuticals | Phase 3 | Obesity | Recruiting |
| 2026-12-01in 98 d | A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | ZNTLK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Phase 2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Recruiting |
| 2026-12-02in 99 d | Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin | AZNAstraZeneca | Phase 1 | Kidney Failure | Not yet recruiting |
| 2026-12-02in 99 d | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | PFEPfizer | Phase 3 | Castration-Resistant Prostate Cancer | Recruiting |
| 2026-12-02in 99 d | A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | PFEPfizer | Phase 3 | Alopecia Areata | Active, not recruiting |
| 2026-12-03in 100 d | A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease | 4523.TEisai Inc. | Phase 2 | Alzheimer's Disease | Active, not recruiting |
| 2026-12-03in 100 d | A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body | REGNRegeneron Pharmaceuticals | Phase 2 | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | Active, not recruiting |
| 2026-12-04in 101 d | A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function | PFEPfizer | Phase 1 | Healthy Participants | Recruiting |
| 2026-12-04in 101 d | A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine | PFEPfizer | Phase 3 | Lyme Disease | Recruiting |
| 2026-12-04in 101 d | A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults | REGNRegeneron Pharmaceuticals | Phase 1 | Healthy Volunteers With Hyperlipidemia | Active, not recruiting |
| 2026-12-05in 102 d | A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants | BMYBristol-Myers Squibb | Phase 1 | Healthy Female Participants | Not yet recruiting |
| 2026-12-06in 103 d | Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule. | AZNAstraZeneca | — | Lung Malignancy | Active, not recruiting |
| 2026-12-08in 105 d | A Study to Learn About How Different Forms of Study Medicine Prifetrastat Are Taken Up Into the Blood in Healthy Adults | PFEPfizer | Phase 1 | Healthy Participant | Recruiting |
| 2026-12-09in 106 d | Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | INCYIncyte Corporation | Phase 1 | Hidradenitis Suppurativa | Recruiting |
| 2026-12-09in 106 d | Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and Acceptance | NVONovo Nordisk A/S | Phase 1 | Healthy Participants | Not yet recruiting |
| 2026-12-11in 108 d | A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | PFESeagen, a wholly owned subsidiary of Pfizer | Phase 2 | Urothelial Carcinoma | Recruiting |
| 2026-12-12in 109 d | LTFU Study of Subjects Who Received GRNOPC1 | LCTXLineage Cell Therapeutics, Inc. | — | Spinal Cord Injuries | Active, not recruiting |
| 2026-12-13in 110 d | Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | NVONovo Nordisk A/S | Phase 1 | Obesity | Recruiting |
| 2026-12-14in 111 d | Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | AMGNAmgen | Phase 3 | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting |
| 2026-12-14in 111 d | Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | AZNAstraZeneca | — | Pulmonary Disease, Chronic Obstructive | Active, not recruiting |
| 2026-12-14in 111 d | Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | BMYBristol-Myers Squibb | Phase 2 | Heart Failure | Active, not recruiting |
| 2026-12-14in 111 d | Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US | BMYBristol-Myers Squibb | — | Hypertrophic Cardiomyopathy | Recruiting |
| 2026-12-14in 111 d | A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function | BMYBristol-Myers Squibb | Phase 1 | Kidney Failure, Chronic | Not yet recruiting |
| 2026-12-14in 111 d | ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | NVONovo Nordisk A/S | Phase 3 | Cardiovascular Risk, Acute Myocardial Infarction (AMI) | Recruiting |
| 2026-12-14in 111 d | A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity | NVONovo Nordisk A/S | Phase 2 | Overweight | Active, not recruiting |
| 2026-12-15in 112 d | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | EXELExelixis | Phase 3 | Non-Clear Cell Renal Cell Carcinoma | Active, not recruiting |
| 2026-12-15in 112 d | A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows | IPN.PAIpsen | Phase 3 | Moderate to Severe Glabellar Lines | Recruiting |
| 2026-12-15in 112 d | A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows | IPN.PAIpsen | Phase 3 | Moderate to Severe Glabellar Lines | Recruiting |
| 2026-12-15in 112 d | US Post-Market Surveillance Study of the Surfacer System | MMSIMerit Medical Systems, Inc. | — | Venous Disease | Recruiting |
| 2026-12-15in 112 d | A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months | PFEPfizer | — | Pneumococcal Disease | Active, not recruiting |
| 2026-12-17in 114 d | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | AMGNAmgen | Phase 1 | Solid Tumors | Active, not recruiting |
| 2026-12-17in 114 d | A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants | BMYBristol-Myers Squibb | Phase 1 | Healthy Volunteers | Recruiting |
| 2026-12-17in 114 d | A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) | IPN.PAIpsen | Phase 3 | Primary Biliary Cholangitis | Active, not recruiting |
| 2026-12-17in 114 d | A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease | SNYSanofi | Phase 2 | Crohn's Disease | Recruiting |
| 2026-12-17in 114 d | A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis | SNYSanofi | Phase 2 | Ulcerative Colitis | Recruiting |
| 2026-12-17in 114 d | A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults | SRRKScholar Rock, Inc. | Phase 1 | Healthy | Recruiting |
| 2026-12-18in 115 d | A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine | ABBVAbbVie | Phase 2 | Migraine | Recruiting |
| 2026-12-22in 119 d | Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102) | ENSCEnsysce Biosciences | Phase 1 | Pharmacokinetics, Healthy Volunteer | Recruiting |
| 2026-12-23in 120 d | A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease | SNYSanofi | Phase 2 | Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion | Recruiting |
| 2026-12-24in 121 d | Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes | PODDInsulet Corporation | Not applicable | Type 2 Diabetes | Recruiting |
| 2026-12-25in 122 d | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort | AZNAstraZeneca | Phase 1 | Chronic Kidney Disease | Recruiting |
| 2026-12-25in 122 d | A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | PFEPfizer | Phase 2 | Chronic Spontaneous Urticaria | Recruiting |
| 2026-12-25in 122 d | Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF) | SNYSanofi | Not applicable | Type 1 Diabetes | Recruiting |
| 2026-12-26in 123 d | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | INCYIncyte Corporation | Phase 3 | Hidradenitis Suppurativa | Active, not recruiting |
| 2026-12-26in 123 d | A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity | NVONovo Nordisk A/S | Phase 1 | Obesity | Recruiting |
| 2026-12-27in 124 d | A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants | BMYBristol-Myers Squibb | Phase 1 | Healthy Volunteers | Recruiting |
| 2026-12-28in 125 d | Lorlatinib Continuation Study | PFEPfizer | Phase 4 | Lung Cancer | Active, not recruiting |
| 2026-12-28in 125 d | A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | PFEPfizer | Phase 3 | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Active, not recruiting |
| 2026-12-29in 126 d | A Study to Evaluate ALN-4285 in Adult Healthy Volunteers | ALNYAlnylam Pharmaceuticals | Phase 1 | Healthy Volunteers | Recruiting |
| 2026-12-29in 126 d | A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | REGNRegeneron Pharmaceuticals | Phase 2 | Hypercholesterolemia | Recruiting |
| 2026-12-30in 127 d | A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease | 4507.TShionogi | Phase 2 | Respiratory Syncytial Virus | Recruiting |
| 2026-12-30in 127 d | Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression | ANEBAnebulo Pharmaceuticals | — | Acute Cannabis-induced CNS Depression | Recruiting |
| 2026-12-30in 127 d | Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study | BJDXBluejay Diagnostics, Inc. | — | Sepsis, Septic Shock | Recruiting |
| 2026-12-30in 127 d | NEO100 and High-Grade Meningioma | NTHINeonc Technologies, Inc. | Phase 2 | Residual, Progressive or Recurrent Grade II or III Meningioma | Recruiting |
| 2026-12-30in 127 d | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) | PFEPfizer | Phase 1/2 | Breast Cancer | Active, not recruiting |
| 2026-12-30in 127 d | Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | PFEPfizer | Phase 3 | Breast Cancer | Active, not recruiting |
| 2026-12-30in 127 d | A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer | PFEPfizer | — | Breast Cancer | Active, not recruiting |
| 2026-12-30in 127 d | Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran) | PFEPfizer | — | COVID-19 | Active, not recruiting |
| 2026-12-30in 127 d | Data Collection Study to Review Novel Methods for Diagnosing Obstructive Sleep Apnea | RMDResMed | — | Obstructive Sleep Apnea | Recruiting |
| 2026-12-30in 127 d | Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | SLSSellas Life Sciences Group | Phase 1/2 | Hematologic Malignancies | Recruiting |
| 2026-12-30in 127 d | A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | SOBI.STSwedish Orphan Biovitrum | Phase 2 | VEXAS, VEXAS Syndrome | Active, not recruiting |
| 2026-12-30in 127 d | BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures | SUPNSupernus Pharmaceuticals, Inc. | Phase 1/2 | Focal Impaired Awareness Seizures | Active, not recruiting |
| 2026-12-30in 127 d | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | TCRXTScan Therapeutics, Inc. | Phase 1 | Head and Neck Cancer | Active, not recruiting |
| 2026-12-31in 128 d | Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation | 000100.KSYuhan Corporation | — | Lung Cancer | Active, not recruiting |
| Dec 2026≤ 128 d | Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin | 068270.KSCelltrion | Phase 3 | Type 2 Diabetes | Recruiting |
| 2026-12-31in 128 d | Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea | 4507.TShionogi | Phase 2 | Sleep Apnea | Active, not recruiting |
| 2026-12-31in 128 d | A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's Disease | 4523.TEisai Inc. | — | Alzheimer's Disease | Not yet recruiting |
| Dec 2026≤ 128 d | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL | AAPGAscentage Pharma Group Inc. | Phase 2 | Chronic Lymphocytic Leukemia | Recruiting |
| 2026-12-31in 128 d | Global Trial in APG2575 for Patients With CLL/SLL | AAPGAscentage Pharma Group Inc. | Phase 3 | Chronic Lymphocytic Leukemia | Recruiting |
| Dec 2026≤ 128 d | Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children | ABBVAbbVie | Phase 2 | Irritable Bowel Syndrome | Recruiting |
| 2026-12-31in 128 d | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | ABBVAbbVie | Phase 1 | Myeloproliferative Neoplasm | Active, not recruiting |
| Dec 2026≤ 128 d | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | ABBVAbbVie | Phase 2/3 | Age-Related Macular Degeneration | Active, not recruiting |
| Dec 2026≤ 128 d | A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Greece | ABBVAbbVie | — | Acute Myeloid Leukemia | Recruiting |
| Dec 2026≤ 128 d | Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant | ABBVAbbVie | — | Diabetic Macular Edema | Active, not recruiting |
| Dec 2026≤ 128 d | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | ABBVAbbVie | Phase 2 | Colorectal Cancer | Active, not recruiting |
| Dec 2026≤ 128 d | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | ABBVAbbVie | Phase 3 | Hidradenitis Suppurativa | Active, not recruiting |
| Dec 2026≤ 128 d | An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC) | ABBVAbbVie | — | Ulcerative Colitis | Recruiting |
| Dec 2026≤ 128 d | Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease | ABVXAbivax S.A. | Phase 2 | Moderately to Severely Active Crohn Disease | Recruiting |
| Dec 2026≤ 128 d | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma | ALDXAldeyra Therapeutics, Inc. | Phase 3 | Primary Vitreoretinal Lymphoma | Recruiting |
| 2026-12-31in 128 d | Invisalign® System with Mandibular Advancement | ALGNAlign Technology, Inc. | Not applicable | Class II Malocclusion, Mandibular Advancement, Mandibular Retrognathism, Excessive Overjet | Recruiting |
| Dec 2026≤ 128 d | A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder | ALZNAlzamend Neuro, Inc. | Phase 1/2 | Bipolar Disorder | Recruiting |
| 2026-12-31in 128 d | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) | AMGNAmgen | Phase 1 | Lung Cancer | Active, not recruiting |
| Dec 2026≤ 128 d | Acute Pulmonary Embolism Treatment With the AlphaVac Multipurpose Mechanical Aspiration System and the AlphaReturn Blood Management System: Evaluation of Safety and Effectiveness | ANGOAngiodynamics, Inc. | Not applicable | Pulmonary Embolism Acute | Recruiting |
| 2026-12-31in 128 d | An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) | ANNXAnnexon, Inc. | Phase 3 | Guillain-Barre Syndrome | Recruiting |
| Dec 2026≤ 128 d | Study of ALTO-300 in MDD | ANROAlto Neuroscience | Phase 2 | Major Depressive Disorder | Recruiting |
| Dec 2026≤ 128 d | An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis | APGEApogee Therapeutics, Inc. | Phase 1 | Atopic Dermatitis | Active, not recruiting |
| Dec 2026≤ 128 d | Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 | ARWRArrowhead Pharmaceuticals | Phase 1 | Spinocerebellar Ataxia Type 2 | Active, not recruiting |
| Dec 2026≤ 128 d | C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV | AVIRAtea Pharmaceuticals, Inc. | Phase 3 | HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C | Active, not recruiting |
| Dec 2026≤ 128 d | Study of AT-587 in Healthy Subjects | AVIRAtea Pharmaceuticals, Inc. | Phase 1 | Hepatitis E | Recruiting |
| Dec 2026≤ 128 d | AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF | AVLNAvalyn Pharma Inc. | Phase 2 | Idiopathic Pulmonary Fibrosis | Recruiting |
| Dec 2026≤ 128 d | Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends | AXGNAxogen Corporation | Not applicable | Symptomatic Neuroma, Amputation, Chronic Nerve Pain | Active, not recruiting |
| Dec 2026≤ 128 d | Nerve Protection Evaluation: Revision Cubital Tunnel Syndrome Decompression | AXGNAxogen Corporation | Not applicable | Recurrent Cubital Tunnel Syndrome, Recalcitrant Cubital Tunnel Syndrome | Active, not recruiting |
| Dec 2026≤ 128 d | Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol | AXSMAxsome Therapeutics, Inc. | Phase 3 | Binge-Eating Disorder | Recruiting |
| Dec 2026≤ 128 d | Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | AXSMAxsome Therapeutics, Inc. | Phase 3 | Excessive Sleepiness, Shift-work Disorder | Recruiting |
| 2026-12-31in 128 d | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab | AZNAstraZeneca | Phase 3 | Cancer | Enrolling by invitation |
| 2026-12-31in 128 d | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | AZNAstraZeneca | Phase 1 | Solid Tumors | Active, not recruiting |
| 2026-12-31in 128 d | Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany | AZNAstraZeneca | — | Heart Failure | Active, not recruiting |
| 2026-12-31in 128 d | RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil | AZNAstraZeneca | — | Lung Cancer | Recruiting |
| 2026-12-31in 128 d | AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database | AZNAstraZeneca | — | Chronic Lymphocytic Leukemia | Recruiting |
| 2026-12-31in 128 d | TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation | AZNAstraZeneca | — | Bladder Cancer | Recruiting |
| 2026-12-31in 128 d | A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients | AZNAstraZeneca | — | Pan-tumor(NSCLC, GYN Cancers, BTC and UC) | Recruiting |
| 2026-12-31in 128 d | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | BCAXBicara Therapeutics | Phase 1 | Head and Neck Cancer | Recruiting |
| Dec 2026≤ 128 d | Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells | BCDABioCardia, Inc. | Phase 1/2 | Heart Failure | Active, not recruiting |
| Dec 2026≤ 128 d | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | BEAMBeam Therapeutics Inc. | Phase 1/2 | Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia | Active, not recruiting |
| 2026-12-31in 128 d | A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan | BMYBristol-Myers Squibb | — | Lung Cancer | Active, not recruiting |
| 2026-12-31in 128 d | A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer | BMYBristol-Myers Squibb | — | Gastric Cancer | Active, not recruiting |
| 2026-12-31in 128 d | Real-world Patient Reported Outcomes Among Patients Treated With Camzyos | BMYBristol-Myers Squibb | — | Hypertrophic Cardiomyopathy | Recruiting |
| 2026-12-31in 128 d | Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM) | BMYBristol-Myers Squibb | — | Cardiomyopathy | Recruiting |
| Dec 2026≤ 128 d | A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD) | BRTXBioRestorative Therapies | Phase 2 | Lumbar Disc Disease | Recruiting |
| 2026-12-31in 128 d | EEG Abnormalities in Adult ICU Patients With High Risk of Delirium | CBLLCeribell Inc. | — | Delirium in the Intensive Care Unit | Recruiting |
| 2026-12-31in 128 d | CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) | CEROCERo Therapeutics Holdings, Inc. | Phase 1 | Acute Myeloid Leukemia | Recruiting |
| Dec 2026≤ 128 d | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus | CGEMCullinan Therapeutics Inc. | Phase 1 | Systemic Lupus Erythematosus | Recruiting |
| Dec 2026≤ 128 d | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | CMPXCompass Therapeutics | Phase 1 | Lung Cancer | Recruiting |
| Dec 2026≤ 128 d | BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears | CNMDCONMED Corporation | Not applicable | Rotator Cuff Tears | Recruiting |
| Dec 2026≤ 128 d | CT-95 in Advanced Cancers Associated With Mesothelin Expression | CNTXContext Therapeutics Inc. | Phase 1 | Ovarian Cancer | Recruiting |
| Dec 2026≤ 128 d | Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | CORTCorcept Therapeutics | Phase 2 | Cushing Syndrome | Active, not recruiting |
| Dec 2026≤ 128 d | Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | DCTHDelcath Systems Inc. | Phase 2 | Colorectal Cancer | Recruiting |
| Dec 2026≤ 128 d | Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) | DMACDiaMedica Therapeutics Inc | Phase 2/3 | Acute Stroke, Ischemic Stroke, Stroke | Recruiting |
| Dec 2026≤ 128 d | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) | DNLIDenali Therapeutics Inc. | Phase 1/2 | Frontotemporal Dementia | Active, not recruiting |
| Dec 2026≤ 128 d | A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy | DNTHDianthus Therapeutics | Phase 2 | Multifocal Motor Neuropathy | Active, not recruiting |
| 2026-12-31in 128 d | Evaluation of Safety of Acellular Dermal Matrix(ADM) in Breast Reconstruction | DOFG.OLDOF Inc. | — | Breast Cancer | Recruiting |
| Dec 2026≤ 128 d | A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia | DSGNDesign Therapeutics, Inc. | Phase 1/2 | Friedreich Ataxia | Recruiting |
| Dec 2026≤ 128 d | Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B | DTILPrecision BioSciences, Inc. | Phase 1 | HEPATITIS B CHRONIC | Recruiting |
| Dec 2026≤ 128 d | A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | EIKNEikon Therapeutics | Phase 2 | Lung Cancer | Active, not recruiting |
| Dec 2026≤ 128 d | EluPro Antibiotic-Eluting BioEnvelope Registry | ELUTElutia Inc. | — | Cardiac Arrhythmias | Active, not recruiting |
| Dec 2026≤ 128 d | A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus | ENTAEnanta Pharmaceuticals, Inc | Phase 2 | Respiratory Syncytial Virus | Recruiting |
| Dec 2026≤ 128 d | A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). | EPRXEupraxia Pharmaceuticals Inc. | Phase 1/2 | Eosinophilic Esophagitis | Recruiting |
| 2026-12-31in 128 d | Clinical Study on Tissue Preservation in Breast Augmentation and Reconstruction | ESTAEstablishment Labs | — | Breast Augmentation and Breast Reconstruction, Mammaplasty, Breast Augmentation, Tissue Preservation | Enrolling by invitation |
| Dec 2026≤ 128 d | COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction | EWEdwards Lifesciences | Not applicable | Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration | Recruiting |
| 2026-12-31in 128 d | Clinical Study of Edwards Cardioband FIT Valve Repair System | EWEdwards Lifesciences | Not applicable | Tricuspid Regurgitation | Active, not recruiting |
| Dec 2026≤ 128 d | Real World Data Collection on the INSPIRIS RESILIA Aortic Valve | EWEdwards Lifesciences | — | Aortic Valve Disease | Recruiting |
| 2026-12-31in 128 d | A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo | FBRXForte Biosciences, Inc. | Phase 1 | Vitiligo | Recruiting |
| Dec 2026≤ 128 d | Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With T2DM | GAIAGaia AG | Not applicable | Type 2 Diabetes | Active, not recruiting |
| Dec 2026≤ 128 d | A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients | GEHCGE Healthcare | Phase 1/2 | Coronary Artery Disease | Recruiting |
| 2026-12-31in 128 d | Non-Invasive Blood Pressure Accuracy Study for Adult Subject Populations | GEHCGE Healthcare | Not applicable | Blood Pressure, Blood Pressure Measurement | Recruiting |
| 2026-12-31in 128 d | NIBP Study for Neonate and Pediatric Subject Populations | GEHCGE Healthcare | Not applicable | Blood Pressure, Blood Pressure Measurement | Recruiting |
| 2026-12-31in 128 d | NIBP Accuracy Study for Adult Subject Populations | GEHCGE Healthcare | Not applicable | Blood Pressure Measurement, Blood Pressure | Recruiting |
| 2026-12-31in 128 d | Screening for High Frequency Malignant Disease | GHGuardant Health, Inc. | — | Lung Cancer | Active, not recruiting |
| Dec 2026≤ 128 d | Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment | GILDGilead Sciences | Phase 1 | Solid Tumors | Recruiting |
| Dec 2026≤ 128 d | Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | GILDGilead Sciences | Phase 3 | Breast Cancer | Active, not recruiting |
| Dec 2026≤ 128 d | Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors | GILDGilead Sciences | Phase 1 | Solid Tumors | Active, not recruiting |
| Dec 2026≤ 128 d | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | GNLXGenelux Corporation | Phase 3 | Ovarian Cancer | Recruiting |
| Dec 2026≤ 128 d | ProGo Menopause Wellbeing Study | HBC.OLHofseth Biocare ASA | Not applicable | Menopause Related Conditions | Not yet recruiting |
| 2026-12-31in 128 d | Using CTA Measures to Define Cardiac Risk In NFL Alumni | HTFLHeartFlow, Inc. | — | Coronary Artery Disease | Recruiting |
| 2026-12-31in 128 d | A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers | IARTIntegra LifeSciences Corporation | Not applicable | Diabetic Foot Ulcer, Venous Leg Ulcer | Enrolling by invitation |
| Dec 2026≤ 128 d | Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury | ICUSeaStar Medical | Not applicable | Acute Kidney Injury | Recruiting |
| 2026-12-31in 128 d | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) | INOInovio Pharmaceuticals | Phase 1/2 | Glioblastoma | Active, not recruiting |
| 2026-12-31in 128 d | An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) | INSMInsmed Incorporated | Phase 2/3 | Pulmonary Arterial Hypertension | Active, not recruiting |
| Dec 2026≤ 128 d | A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) | IONSIonis Pharmaceuticals, Inc. | Phase 3 | Hereditary Angioedema | Active, not recruiting |
| 2026-12-31in 128 d | Open Nipple Sparing Mastectomy (NSM) | ISRGIntuitive Surgical | — | Nipple Sparing Mastectomy | Active, not recruiting |
| 2026-12-31in 128 d | Use of Force Feedback Instruments With the da Vinci Surgical System, Model IS5000 for Mitral Valve Repair | ISRGIntuitive Surgical | Not applicable | Mitral Regurgitation (MR) | Enrolling by invitation |
| 2026-12-31in 128 d | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | JAZZJazz Pharmaceuticals | Phase 2 | Breast Cancer | Recruiting |
| Dec 2026≤ 128 d | Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension | KARDKardigan, Inc. | Phase 2 | Hypertension | Recruiting |
| Dec 2026≤ 128 d | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | KPTIKaryopharm Therapeutics Inc | Phase 2 | Diffuse Large B-Cell Lymphoma | Active, not recruiting |
| Dec 2026≤ 128 d | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | KPTIKaryopharm Therapeutics Inc | Phase 2/3 | Diffuse Large B-Cell Lymphoma | Active, not recruiting |
| Dec 2026≤ 128 d | A Study Assessing KB407 for the Treatment of Cystic Fibrosis | KRYSKrystal Biotech, Inc. | Phase 1 | Cystic Fibrosis | Recruiting |
| Dec 2026≤ 128 d | A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis | KRYSKrystal Biotech, Inc. | Phase 1/2 | Neurotrophic Keratitis | Recruiting |
| Dec 2026≤ 128 d | A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa | KRYSKrystal Biotech, Inc. | Phase 3 | Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa | Recruiting |
| Dec 2026≤ 128 d | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | KURAKura Oncology, Inc. | Phase 1 | Acute Myeloid Leukemia | Recruiting |
| Dec 2026≤ 128 d | First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants | KYMRKymera Therapeutics, Inc. | Phase 1 | Healthy Participants | Recruiting |
| Dec 2026≤ 128 d | A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors | LLYEli Lilly and Company | Phase 1 | Breast Cancer | Recruiting |
| Dec 2026≤ 128 d | A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | LLYEli Lilly and Company | Phase 2 | Type 2 Diabetes | Recruiting |
| Dec 2026≤ 128 d | A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes | LLYEli Lilly and Company | Phase 1 | Type 1 Diabetes | Recruiting |
| Dec 2026≤ 128 d | A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus | LLYEli Lilly and Company | Phase 1 | Diabetes Mellitus, Insulin Sensitivity | Active, not recruiting |
| Dec 2026≤ 128 d | A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | LLYEli Lilly and Company | Phase 2 | Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms | Recruiting |
| Dec 2026≤ 128 d | A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy | LLYEli Lilly and Company | Phase 1 | Overweight | Active, not recruiting |
| Dec 2026≤ 128 d | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight | LLYEli Lilly and Company | Phase 1 | Obesity | Recruiting |
| Dec 2026≤ 128 d | A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | LTRNLantern Pharma Inc. | Phase 2 | Lung Cancer | Recruiting |
| 2026-12-31in 128 d | Zephyr Valve Registry (ZEVR) | LUNGPulmonx Corporation | — | Emphysema | Active, not recruiting |
| Dec 2026≤ 128 d | Gene Therapy for ACM Due to a PKP2 Pathogenic Variant | LXEOLexeo Therapeutics | Phase 1/2 | Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC | Active, not recruiting |
| Dec 2026≤ 128 d | Safety and Efficacy of VDPHL01 in Males With AGA | MANEVeradermics, Inc. | Phase 3 | Androgenetic Alopecia, AGA, Male Pattern Baldness | Active, not recruiting |
| Dec 2026≤ 128 d | A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | MDGLMadrigal Pharmaceuticals, Inc. | Phase 3 | MASH / Nonalcoholic Steatohepatitis | Active, not recruiting |
| Dec 2026≤ 128 d | A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) | MDWDMediWound Ltd | Phase 3 | Venous Leg Ulcer (VLU) | Recruiting |
| 2026-12-31in 128 d | MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia | MNOVMediciNova | Phase 2 | Type 2 Diabetes | Active, not recruiting |
| Dec 2026≤ 128 d | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | MNPRMonopar Therapeutics | Phase 1 | Solid Tumors | Recruiting |
| 2026-12-31in 128 d | A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations | MRNAModernaTX, Inc. | Phase 4 | COVID-19 | Recruiting |
| Dec 2026≤ 128 d | Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer | NVCTNuvectis Pharma, Inc. | Phase 1 | Lung Cancer | Recruiting |
| 2026-12-31in 128 d | Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya® | NVONovo Nordisk A/S | — | Adult Growth Hormone Deficiency | Active, not recruiting |
| 2026-12-31in 128 d | A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy Participants | NVONovo Nordisk A/S | Phase 1 | Heart Failure | Recruiting |
| 2026-12-31in 128 d | Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma | NVONovo Nordisk A/S | — | Medullary Thyroid Carcinoma | Enrolling by invitation |
| Dec 2026≤ 128 d | A Phase 1 Study of LNCB74 in Advanced Solid Tumors | NXTCNextCure, Inc. | Phase 1 | Ovarian Cancer | Recruiting |
| Dec 2026≤ 128 d | BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | OBIOOrchestra BioMed, Inc | Not applicable | Hypertension | Recruiting |
| Dec 2026≤ 128 d | Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria | OMEROmeros Corporation | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | Active, not recruiting |
| 2026-12-31in 128 d | A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors | ONCBeOne Medicines | Phase 1 | Solid Tumors | Recruiting |
| Dec 2026≤ 128 d | ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC | ORICORIC Pharmaceuticals | Phase 1 | Solid Tumors | Recruiting |
| Dec 2026≤ 128 d | Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System | PENPenumbra Inc. | — | Pulmonary Embolism | Recruiting |
| 2026-12-31in 128 d | PF-07104091 as a Single Agent and in Combination Therapy | PFEPfizer | Phase 2 | Lung Cancer | Active, not recruiting |
| 2026-12-31in 128 d | Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy | PFEPfizer | — | ATTR Amyloidosis | Active, not recruiting |
| 2026-12-31in 128 d | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | PFEPfizer | Phase 3 | Lung Cancer | Active, not recruiting |
| 2026-12-31in 128 d | Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies | PFEPfizer | Phase 2 | Breast Cancer | Active, not recruiting |
| 2026-12-31in 128 d | Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002) | PFEPfizer | Phase 1 | Breast Cancer | Active, not recruiting |
| 2026-12-31in 128 d | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) | PFEPfizer | Phase 1/2 | Breast Cancer | Active, not recruiting |
| Dec 2026≤ 128 d | Safety and Early Signs of Efficacy of IL12-L19L19. | PHIL.MIPhilogen S.p.A. | Phase 1 | Solid Tumors | Recruiting |
| Dec 2026≤ 128 d | Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss Treatment | PHN.MIPharmanutra S.p.a. | Not applicable | Obesity | Recruiting |
| 2026-12-31in 128 d | CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation | PLSEPulse Biosciences, Inc. | Not applicable | Atrial Fibrillation | Recruiting |
| Dec 2026≤ 128 d | PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) | PMNProMis Neurosciences, Inc | Phase 1 | Alzheimer's Disease | Active, not recruiting |
| 2026-12-31in 128 d | Evaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1D | PODDInsulet Corporation | Not applicable | Type 1 Diabetes | Recruiting |
| Dec 2026≤ 128 d | A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine | PRAXPraxis Precision Medicines | Phase 3 | Developmental and Epileptic Encephalopathy 1 | Active, not recruiting |
| Dec 2026≤ 128 d | A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety | PRAXPraxis Precision Medicines | Phase 3 | Epilepsy and Seizure Disorders | Recruiting |
| Dec 2026≤ 128 d | A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants | RCUSArcus Biosciences, Inc. | Phase 1 | Healthy Volunteers | Not yet recruiting |
| Dec 2026≤ 128 d | ASV Therapy for Insomnia | RMDResMed | Not applicable | Insomnia, Insomnia (Moderate) | Recruiting |
| 2026-12-31in 128 d | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | RVMDRevolution Medicines, Inc. | Phase 1 | Lung Cancer | Recruiting |
| 2026-12-31in 128 d | Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During Pregnancy | SNYSanofi | — | Pertussis (Whooping Cough) | Active, not recruiting |
| 2026-12-31in 128 d | Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy | SRPTSarepta Therapeutics, Inc. | Phase 1/2 | Myotonic Dystrophy 1 | Recruiting |
| 2026-12-31in 128 d | Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder | SUPNSupernus Pharmaceuticals, Inc. | Phase 2 | Major Depressive Disorder | Recruiting |
| Dec 2026≤ 128 d | Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age | TARAProtara Therapeutics | Phase 2 | Lymphatic Malformation | Recruiting |
| 2026-12-31in 128 d | Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE) | TARSTarsus Pharmaceuticals, Inc. | Phase 2 | Ocular Rosacea | Enrolling by invitation |
| 2026-12-31in 128 d | Outcomes Following Combined Adductoplasty™ and Lapiplasty® (MTA3D) | TMCITreace Medical Concepts, Inc. | Not applicable | Metatarsus Adductus, Hallux Valgus | Recruiting |
| Dec 2026≤ 128 d | This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza | TRAWTraws Pharma, Inc. | Phase 2 | Influenza | Active, not recruiting |
| Dec 2026≤ 128 d | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | UTHRUnited Therapeutics | Phase 3 | Hypertension | Enrolling by invitation |
| Dec 2026≤ 128 d | Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | VANIVivani Medical, Inc | Phase 1 | Obesity | Not yet recruiting |
| 2026-12-31in 128 d | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | VIRVir Biotechnology, Inc. | Phase 3 | Viral Hepatitis | Active, not recruiting |
| Dec 2026≤ 128 d | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide | VIRVir Biotechnology, Inc. | Phase 3 | Viral Hepatitis | Active, not recruiting |
| 2026-12-31in 128 d | Safety and Efficacy of Epicardial Implantation of Collagen Membranes With Allogeneic Adipose Derived Stem Cells | VIS.MCViscofan | Phase 1 | Heart Failure | Not yet recruiting |
| Dec 2026≤ 128 d | Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder | VNDAVanda Pharmaceuticals | Phase 3 | Social Anxiety Disorder (SAD) | Active, not recruiting |
| 2026-12-31in 128 d | Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease | VRTXVertex Pharmaceuticals Incorporated | — | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Active, not recruiting |
| Dec 2026≤ 128 d | Outcomes Study of the Trabecular Metal (TM) Reverse Shoulder System | ZBHZimmer Biomet | — | Osteoarthritis | Active, not recruiting |
| Dec 2026≤ 128 d | Comprehensive Reverse Shoulder Data Collection | ZBHZimmer Biomet | — | Osteoarthritis | Enrolling by invitation |
| Dec 2026≤ 128 d | Database Retrieval for the Comprehensive Shoulder | ZBHZimmer Biomet | — | Osteoarthritis | Active, not recruiting |
| Dec 2026≤ 128 d | Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | ZBHZimmer Biomet | Not applicable | Osteoarthritis | Active, not recruiting |
| Dec 2026≤ 128 d | A.L.P.S. Clavicle Plating System PMCF | ZBHZimmer Biomet | Not applicable | Clavicle Fracture, Clavicle Injury | Active, not recruiting |
| Dec 2026≤ 128 d | Persona IQ Cohort Study | ZBHZimmer Biomet | — | Osteo Arthritis Knee, Knee Arthritis, Monitoring Orthopedic Devices, Total Knee Arthroplasty, Total Knee Replacement | Active, not recruiting |
| 2026-12-31in 128 d | Comprehensive SRS Regenerex Tissue Attachment | ZBHZimmer Biomet | — | Arthroplasty Complications, Osteo Arthritis Shoulders | Active, not recruiting |
